Compare PFBC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFBC | KALV |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | 324 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | PFBC | KALV |
|---|---|---|
| Price | $94.65 | $19.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $100.67 | $32.60 |
| AVG Volume (30 Days) | 86.8K | ★ 1.1M |
| Earning Date | 04-22-2026 | 05-09-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $2.94 | $187.19 |
| Revenue Next Year | $8.31 | $54.93 |
| P/E Ratio | $8.85 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $75.87 | $9.83 |
| 52 Week High | $103.05 | $21.31 |
| Indicator | PFBC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 67.29 | 62.29 |
| Support Level | $92.90 | $14.66 |
| Resistance Level | $96.63 | $21.31 |
| Average True Range (ATR) | 1.96 | 1.35 |
| MACD | 0.54 | 0.14 |
| Stochastic Oscillator | 97.22 | 75.14 |
Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking, which include Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.